Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659606 · ClinicalTrials.gov registry record · Phase 2
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
A Phase 2 study of Aplastic Anemia and Dyskeratosis Congenita, sponsored by Boston Children's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 14
- Study locations
NCT01659606: Active Phase 2 study of Aplastic Anemia and Dyskeratosis Congenita, sponsored by Boston Children's Hospital.
NCT01659606 is a Phase 2 study of Aplastic Anemia and Dyskeratosis Congenita that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 40 participants, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target. The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01659606, a Phase 2 study of Aplastic Anemia and Dyskeratosis Congenita, is active but no longer recruiting, sponsored by Boston Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 14
- Study locations
Study Summary
Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically causing failure of the blood system. Lung disease, liver disease and cancer are other frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood system but can make the lung and liver disease and risk of cancer worse, because of DNA damaging agents such as alkylators and radiation that are typically used in the procedure. Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA damaging agents in patients with DC, and still have a successful BMT. In this protocol we will test whether a regimen that avoids DNA alkylators and radiation can permit successful BMT without compromising survival in patients with DC.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- BIOLOGICAL alemtuzumab
- DRUG Cyclosporins
Study Locations (14)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital (pediatric patients) - Boston
- Dana-Farber Cancer Institute (adult patients) - Boston
Other
- Oslo University Hospital - Oslo
- Karolinska University Hospital - Stockholm
California
- Children's Hospital Los Angeles - Los Angeles
Illinois
- University of Chicago - Chicago
Missouri
- Children's Mercy Hospital Kansas City - Kansas City
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-07 |
| Est. Completion | 2034-12 |
| Phase | Phase 2 |
What the registry record for NCT01659606 still lists
NCT01659606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target.
The record links to 4 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT01659606 lists 14 locations in 11 states (Massachusetts, Other, California).
Frequently Asked Questions
What is clinical trial NCT01659606 about?
NCT01659606 is a clinical study titled "Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita". Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically causing failure of the blood system. Lung disease, liver disease and cancer are other frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood system but can make the lung an...
What is the current status of trial NCT01659606?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-07. Estimated completion is 2034-12.
What conditions does trial NCT01659606 study?
This clinical trial studies the following conditions: Aplastic Anemia, Dyskeratosis Congenita, Hoyeraal-Hreidarsson Syndrome, Revesz Syndrome.
What interventions are being tested in trial NCT01659606?
The interventions under investigation include: Fludarabine (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), alemtuzumab (BIOLOGICAL), Cyclosporins (DRUG).
Who is sponsoring clinical trial NCT01659606?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01659606 being conducted?
This trial has 14 study locations across California, Illinois, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01659606's enrollment target sits among peer trials
40 9th of 23 higher than 14 of 23 other Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
RECRUITING · Phase 2
-
Haploidentical HCT for Severe Aplastic Anemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia